-
Something wrong with this record ?
Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic
M. Janatova, J. Soukupova, J. Stribrna, P. Kleiblova, M. Vocka, P. Boudova, Z. Kleibl, P. Pohlreich,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT13343
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- DNA-Binding Proteins genetics MeSH
- Exons genetics MeSH
- Genetic Predisposition to Disease * MeSH
- Genes, Neoplasm * MeSH
- Introns genetics MeSH
- DNA, Complementary genetics MeSH
- Humans MeSH
- Molecular Sequence Data MeSH
- DNA Mutational Analysis MeSH
- Ovarian Neoplasms genetics MeSH
- BRCA1 Protein genetics MeSH
- BRCA2 Protein genetics MeSH
- Risk Factors MeSH
- Family MeSH
- Base Sequence MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
Recent studies have conferred that the RAD51C and RAD51D genes, which code for the essential proteins involved in homologous recombination, are ovarian cancer (OC) susceptibility genes that may explain genetic risks in high-risk patients. We performed a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative OC patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population. The analysis involved direct sequencing, high resolution melting and multiple ligation-dependent probe analysis. We identified two (1.2%) and three (1.8%) inactivating germline mutations in both respective genes, two of which (c.379_380insG, p.P127Rfs*28 in RAD51C and c.879delG, p.C294Vfs*16 in RAD51D) were novel. Interestingly, an indicative family cancer history was not present in four carriers. Moreover, the ages at the OC diagnoses in identified mutation carriers were substantially lower than those reported in previous studies (four carriers were younger than 45 years). Further, we also described rare missense variants, two in RAD51C and one in RAD51D whose clinical significance needs to be verified. Truncating mutations and rare missense variants ascertained in OC patients were not detected in 1226 control samples. Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients. Therefore, an RAD51C and RAD51D analysis should be implemented into the comprehensive multi-gene testing for high-risk OC patients, including early-onset OC patients without a family cancer history.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020699
- 003
- CZ-PrNML
- 005
- 20191014125152.0
- 007
- ta
- 008
- 160722s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0127711 $2 doi
- 024 7_
- $a 10.1371/journal.pone.0127711 $2 doi
- 035 __
- $a (PubMed)26057125
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Janatová, Markéta $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 stk2008428924
- 245 10
- $a Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic / $c M. Janatova, J. Soukupova, J. Stribrna, P. Kleiblova, M. Vocka, P. Boudova, Z. Kleibl, P. Pohlreich,
- 520 9_
- $a Recent studies have conferred that the RAD51C and RAD51D genes, which code for the essential proteins involved in homologous recombination, are ovarian cancer (OC) susceptibility genes that may explain genetic risks in high-risk patients. We performed a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative OC patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population. The analysis involved direct sequencing, high resolution melting and multiple ligation-dependent probe analysis. We identified two (1.2%) and three (1.8%) inactivating germline mutations in both respective genes, two of which (c.379_380insG, p.P127Rfs*28 in RAD51C and c.879delG, p.C294Vfs*16 in RAD51D) were novel. Interestingly, an indicative family cancer history was not present in four carriers. Moreover, the ages at the OC diagnoses in identified mutation carriers were substantially lower than those reported in previous studies (four carriers were younger than 45 years). Further, we also described rare missense variants, two in RAD51C and one in RAD51D whose clinical significance needs to be verified. Truncating mutations and rare missense variants ascertained in OC patients were not detected in 1226 control samples. Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients. Therefore, an RAD51C and RAD51D analysis should be implemented into the comprehensive multi-gene testing for high-risk OC patients, including early-onset OC patients without a family cancer history.
- 650 _2
- $a protein BRCA1 $x genetika $7 D019313
- 650 _2
- $a protein BRCA2 $x genetika $7 D024682
- 650 _2
- $a sekvence nukleotidů $7 D001483
- 650 _2
- $a mutační analýza DNA $7 D004252
- 650 _2
- $a komplementární DNA $x genetika $7 D018076
- 650 _2
- $a DNA vazebné proteiny $x genetika $7 D004268
- 650 _2
- $a exony $x genetika $7 D005091
- 650 _2
- $a rodina $7 D005190
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a geny nádorové $7 D052138
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a introny $x genetika $7 D007438
- 650 _2
- $a molekulární sekvence - údaje $7 D008969
- 650 _2
- $a nádory vaječníků $x genetika $7 D010051
- 650 _2
- $a rizikové faktory $7 D012307
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Soukupová, Jana $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0239539
- 700 1_
- $a Stribrna, Jana $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Kleiblová, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. $7 xx0125463
- 700 1_
- $a Vočka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague and Military University Hospital Prague, Prague, Czech Republic. $7 xx0181880
- 700 1_
- $a Zemánková, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0239540
- 700 1_
- $a Kleibl, Zdeněk, $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $d 1969- $7 jo2003183974
- 700 1_
- $a Pohlreich, Petr, $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $d 1947-2015 $7 jn20000710479
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 6 (2015), s. e0127711
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26057125 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20191014125616 $b ABA008
- 999 __
- $a ok $b bmc $g 1155369 $s 945227
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 10 $c 6 $d e0127711 $e 20150609 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- GRA __
- $a NT13343 $p MZ0
- LZP __
- $a Pubmed-20160722